Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86%
- BLOCKSTONE study reaches primary endpoint of fewer people testing positive for flu, with fever and at least one respiratory symptom, when treated with Xofluza versus placebo
Xofluza may represent an important and convenient treatment for both reducing the burden of seasonal flu and limiting the impact of a pandemic
Basel, 2 September 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III BLOCKSTONE study showed preventive treatment with XofluzaTM (baloxavir marboxil) after exposure to an infected household member significantly reduced the risk of people developing flu by 86% versus placebo. The results show just 1.9% of Xofluza-treated household members had flu compared with 13.6% in the placebo-treated group (p<0.0001). This benefit with Xofluza remained statistically significant versus placebo regardless of influenza A subtype (H1N1: 1.1% vs 10.6%, p=0.0023; H3: 2.8% vs. 17.5%, p<0.0001). It was also observed in household contacts who are at high risk of flu-associated complications (2.2% vs 15.4%, p=0.0435), and children under 12 years of age (4.2% vs 15.5%, p=0.0339), who are more vulnerable to developing flu. Xofluza had a comparable safety profile to placebo, with an overall incidence of adverse events being 22.2% for Xofluza and 20.5% for placebo. No serious adverse events were reported for Xofluza. Full results of the study were presented as a late-breaking abstract during the OPTIONS X 2019 congress in Singapore on Sunday 1 September, 2019 (Abstract #11718).1
“As the influenza virus can rapidly infect those around us, limiting the spread of infection within households potentially avoids a significant impact on the wider community – a critical step in the global fight against flu,” said Sandra Horning, M.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We are encouraged by the BLOCKSTONE study, the first to show that Xofluza is an effective preventive treatment following exposure to flu and we look forward to sharing these data with health authorities.”
The BLOCKSTONE study also demonstrated that even when fewer criteria for flu were applied (proportion of participants with flu, with fever OR one or more respiratory symptom), there was still a significant 76% reduction in the risk of household members developing flu with Xofluza versus placebo (5.3% vs 22.4% respectively, p<0.0001).1
Xofluza is the first and only one-dose oral medicine approved to treat flu in otherwise-healthy patients, and the first new flu medicine with a novel proposed mechanism of action approved by the FDA in nearly 20 years. Robust clinical evidence has demonstrated the benefit of Xofluza in several populations (otherwise-healthy, high-risk, children) and treatment settings (symptomatic flu, post-exposure prophylaxis).1-4
BLOCKSTONE is a phase III, randomised, post-exposure prophylaxis study that evaluated a single dose of Xofluza compared with placebo as a preventive treatment for household members (adults and children) who are living with someone with an influenza infection confirmed by a rapid influenza diagnostic test (the ‘index patient’). The study was conducted by Shionogi & Co., Ltd. during the 2018-2019 flu season in Japan.
Participants enrolled in the study were household members of someone who had been diagnosed with influenza. The participants were randomised to receive a single dose of Xofluza (dose according to body weight) or placebo as a preventive measure against developing influenza. The primary endpoint of the study was to evaluate the proportion of participants who tested positive for the influenza virus and had fever, and one or more respiratory symptoms between day one and ten. Secondary endpoints were clinical efficacy, pharmacokinetics and, safety and tolerability.
About Xofluza (baloxavir marboxil)
Xofluza is a first-in-class, one-dose oral medicine with a novel proposed mechanism of action that has demonstrated efficacy in a wide range of influenza viruses, including in vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies.5,6 Unlike other currently available antiviral treatments, Xofluza is the first in a new class of antivirals designed to inhibit the CAP-dependent endonuclease protein, which is essential for viral replication5
Xofluza is currently approved in several countries, including the United States (US), for the treatment of acute, uncomplicated influenza in people 12 years of age and older. In addition, a supplemental New Drug Application (sNDA) for Xofluza as a one-dose oral treatment for people at high risk of complications from flu is under review by the FDA and a decision is expected by 4 November 2019.
Xofluza is being further studied in a phase III development programme, including children under the age of one (NCT03653364), severely ill, hospitalised patients (NCT03684044), as well as to assess the potential to reduce transmission of flu from an infected person to healthy people (NCT03969212).7-9
Xofluza was discovered by Shionogi & Co., Ltd. and is being further developed and commercialised globally in collaboration with the Roche Group (which includes Genentech in the US) and Shionogi & Co., Ltd. Under the terms of this agreement, Roche holds worldwide rights to Xofluza excluding Japan and Taiwan, where rights will be retained exclusively by Shionogi & Co., Ltd.
About Roche in influenza
Influenza, or flu, is one of the most common, yet serious, infectious diseases, representing a significant threat to public health. Globally, seasonal epidemics result in 3 to 5 million cases of severe disease, millions of hospitalisations and up to 650,000 deaths every year.10-14 Central to the threat of flu is the ability of the virus to spread quickly and efficiently from person to person. Limiting the spread of infection is critical in the fight against flu.15
Roche has a long heritage in developing medicines that contribute to public health. We are committed to bringing innovation in the field of infectious diseases, including influenza. Tamiflu® (oseltamivir) has made a significant difference both to the treatment of seasonal influenza as well as in the management of recent pandemics, and we are proud to have brought this innovative medicine to patients. Although vaccines are an important first line of defence in preventing flu, there is a need for new medical options for prophylaxis and treatment. Other antiviral drugs have limitations with respect to efficacy, convenience of dosing and resistance. Roche is committed to addressing the unmet need in this area through its agreement with Shionogi & Co., Ltd. to develop and commercialise Xofluza.
About Roche in infectious disease
Infectious diseases caused by viral or bacterial pathogens are a major cause of death and morbidity worldwide, and constitute an ever-growing medical need. As such, they form a core area of research and development at Roche, with clinical development programmes focused on hepatitis B, influenza and multi-drug resistant bacterial infections. We are committed to developing medicines that aim to be transformative, personalised, and accessible.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
 Ikematsu H, et al. Single-dose baloxavir for the prevention of influenza among household contacts: a randomized, double-blinded, placebo controlled post-exposure prophylaxis study (BLOCKSTONE). OPTIONS X 2019; 2019 Aug 28-Sept 1; Singapore. Abstract #11718.
 Hayden F, et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med 2018; 379:913-923.
 Ison M, et al. CAPSTONE-2 trial. Infectious Disease Week; 2018 Oct 3-7; San Francisco. CA, USA. Abstract #LB16. [Internet; cited 2019 August]. Available from: https://idsa.confex.com/idsa/2018/webprogram/Paper74204.html.
 Baker J, et al. Single-dose baloxavir marboxil for the treatment of influenza in otherwise-healthy children aged 1 to <12 years (miniSTONE-2). OPTIONS X 2019; 2019 Aug 28-Sept 1; Singapore. Abstract #11756.
 Noshi T, et al. In vitro Characterization of Baloxavir Acid, a First-in-Class Cap-dependent Endonuclease Inhibitor of the Influenza Virus Polymerase PA Subunit. Antiviral Research. 2018; 160:109-117.
 Taniguchi K, et al. Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Scientific Reports. 2019; 9:3466.
 ClinicalTrials.gov. Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms (NCT03653364). [Internet; cited 2019 August].
Available from: https://clinicaltrials.gov/ct2/show/NCT03653364.
 ClinicalTrials.gov. Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza (NCT03684044). [Internet; cited 2019 August]. Available from: https://clinicaltrials.gov/ct2/show/NCT03684044.
 ClinicalTrials.gov. Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households (NCT03969212). [Internet; cited 2019 August].
Available from: https://clinicaltrials.gov/ct2/show/NCT03969212.
 WHO 2017. Up to 650 000 people die of respiratory diseases linked to seasonal flu each year. [Internet; cited 2019 August]. Available from: http://www.who.int/mediacentre/news/releases/2017/seasonal-flu/en/.
 WHO 2017. Influenza (seasonal). [Internet; cited 2019 August].
Available from: https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal).
 Baxter D. Evaluating the case for trivalent or quadrivalent influenza vaccines. Hum Vaccin Immunother. 2016; 12:2712.
 Centers for Disease Control and Prevention. Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths Averted by Vaccination in the United States. [Internet; cited 2019 August].
Available from: https://www.cdc.gov/flu/about/disease/2015-16.htm.
 Nair H, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011; 378(9807):1917-30.
 NHS. Flu. [Internet; cited 2019 August]. Available from: https://www.nhs.uk/conditions/flu/.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: email@example.com
- Nicolas Dunant (Head)
- Patrick Barth
- Ulrike Engels-Lange
- Daniel Grotzky
- Karsten Kleine
- Nathalie Meetz
- Barbara von Schnurbein
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Mandalay Resources Corporation tillkännager produktions- och försäljningsresultat för fjärde kvartalet och helåret 2019 samt produktions- och kostnadsprognos för 202018.1.2020 13:30:00 CET | Pressemelding
TORONTO, Jan. 18, 2020 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) tillkännagav idag sina produktions- och försäljningsresultat för fjärde kvartalet och helåret 2019. Under fjärde kvartalet 2019 producerade Mandalay en konsoliderad mängd motsvarande 18 594 säljbara uns guldekvivalent och sålde 16 228 uns guldekvivalent. För helåret som slutade den 31 december 2019 producerade Mandalay 76 659 säljbara uns guldekvivalent och sålde 77 043 uns guldekvivalent. Dominic Duffy, President och Chief Executive Officer för Mandalay, kommenterar, ”Mandalays konsoliderade produktion för helåret 2019 motsvarade den reviderade prognosen som tillkännagavs i oktober 2019 för guld, antimon och guldekvivalenta uns. Björkdal fortsatte sin stabila drift under fjärde kvartalet med en produktion på 10 990 uns säljbart guld och 51 498 uns säljbart guld för helåret, en ungefärlig ökning på 12 % sedan samma period året innan. Vid Costerfield var result
Conditions for Riksbank Bid Procedures Sek Bonds17.1.2020 16:20:00 CET | Press release
Sveriges Riksbank Bid procedure details Government Bonds, 2020-01-23 Maturity date Loan ISIN code Coupon Volume, SEK million 2025-05-12 1058 SE0005676608 2.50 % 500 +/- 250 2028-05-12 1060 SE0009496367 0.75 % 500 +/- 250 Settlement date 2020-01-27 Bids have to be entered by 10.00 on JAN 23, 2020 Highest permitted bid volume: 500 SEK million in issue SGB 1058 and 500 SEK million in issue SGB 1060 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CET) ON JAN 23, 2020. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se
The Board of Directors of Cramo Plc supplements its statement regarding the recommended voluntary public cash tender offer by Boels Topholding B.V. due to the increase in the Offer Price17.1.2020 15:30:00 CET | Press release
Cramo Plc Stock exchange release 17 January 2020 at 4.30 pm (EET) The Board of Directors of Cramo Plc supplements its statement regarding the recommended voluntary public cash tender offer by Boels Topholding B.V. due to the increase in the Offer Price NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR HONG KONG, OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. FOR FURTHER INFORMATION, SEE SECTION "IMPORTANT LEGAL INFORMATION" BELOW. On 11 November 2019, Boels Topholding B.V. (the "Offeror" or "Boels") announced that it will make a recommended voluntary public cash tender offer to acquire all of the issued and outstanding shares in Cramo Plc ("Cramo") that are not held by Cramo or any of its subsidiaries (the "Shares") (the "Tender Offer"). The Board of Directors of Cramo (the "Cramo Board") has on 20 November 2019 issued a statement (the "Statement"
CrossAmerica Partners to Announce Year-End/Fourth Quarter 2019 Earnings Results on February 2517.1.2020 12:45:00 CET | Press release
Allentown, Jan. 17, 2020 (GLOBE NEWSWIRE) -- CrossAmerica Partners to Announce Year-End/Fourth Quarter 2019 Earnings Results on February 25 ALLENTOWN, PA, January 17, 2020 – CrossAmerica Partners LP (NYSE: CAPL) today announced that it will release its year-end/fourth quarter 2019 results after the market closes on Tuesday, February 25, 2020. In conjunction with the news release, management will host a conference call on Wednesday, February 26, at 9:00 a.m. Eastern Time. The conference call numbers are 877-420-2982 or 847-619-6129 and the passcode for both is 5577665#. A live audio webcast of the conference call and the related earnings materials, including reconciliations of any non-GAAP financial measures to GAAP financial measures and any other applicable disclosures, will be available on that same day on the investor section of the CrossAmerica website (www.crossamericapartners.com). To listen to the audio webcast, go to https://caplp.gcs-web.com/webcasts-presentations. After the l
Volta Finance Limited - Update Statement regarding AGM voting17.1.2020 11:38:00 CET | Press release
17 January 2020 Volta Finance Limited (VTA / VTAS) Update Statement regarding AGM voting Information disclosed in accordance with provision 1.D.4 of the 2018 UK Code of Corporate Governance and principle 5.2.4 of the 2019 AIC Code of Corporate Governance. Volta Finance Limited (the “Company”) announced “Results of the Thirteenth Annual General Meeting” on 6 December 2019 and noted the votes against the resolutions to approve the re-election of the directors, Graham Harrison, Stephen Le Page, Paul Meader, Atosa Moini and Paul Varotsis, contained in resolutions 4 to 8 inclusively. The votes against each resolution equated to 37.05% of the total voted by proxy. The Board, through the Company’s corporate broker, has sought to engage with the dissenting shareholders to understand their concerns. Unfortunately, despite multiple efforts, the Board and its adviser have been unsuccessful to date in gaining any response. The Board invites the dissenting shareholders to engage, either directly th
14 nya butiker – stark tillväxt i Elon Ljud & Bild17.1.2020 10:00:00 CET | Pressemelding
Under januari har 14 nya butiker anslutit sig till hemelektronikkedjan Elon Ljud & Bild. Kedjan består nu av över 100 butiker runt om i Sverige. ”Vi ser med stor tillförsikt och glädje att vi attraherar och tillför Elon Ljud & Bild nya lokala aktörer till kedjan”, säger Anneli Sjöstedt, VD på Electra. I november 2019 bytte närmare 100 Audio Video-butiker varumärke och bildade Elon Ljud & Bild. Nu vill fler butiker ansluta sig till hemelektronikkedjan. Vid årsskiftet tecknade 14 nya butiker, spridda över hela landet, avtal med Elon Ljud & Bild. De nya medlemsbutikerna kommer från konkurrerande kedjor eller är befintliga Elon butiker som utvidgar sitt koncept med Elon Ljud & Bild. Butikerna blir på så sätt en komplett leverantör av hemelektronik och vitvaror på sina lokala orter. - Vårt koncept ger kunden full handlingsfrihet utifrån sin egen situation och sina behov, vilket vi vet kommer att vara helt avgörande för en positiv köpupplevelse och långsiktig kundnöjdhet. Det känns som en na